Biomea Fusion (BMEA) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Biomea Fusion (BMEA) over the past year, gaining 23.2% versus a loss of 18.5%. Over five years, BMEA leads with a -88.2% price change compared with -98.3% for KZIA. Kazia Therapeutics is the larger company by market cap ($100.8 million vs $99.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | KZIA |
|---|---|---|
| Share price | $1.37 | $8.82 |
| Market cap | $99.05M | $100.79M |
| 1-day change | +3.79% | -5.06% |
| YTD return | +10.48% | +28.01% |
| 1-year return | -18.45% | +23.18% |
| 5-year return | -88.22% | -98.32% |
| EPS (TTM) | $-0.29 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $17.40 |
| 52-week low | $0.872 | $4.86 |
| Distance from 52-week high | -38.76% | -49.31% |
| Analyst consensus | buy | none |
| Avg. price target upside | +410.95% | +220.41% |
| Average volume | 1.47M | 262.15K |
| Shares outstanding | 72.30M | 11.43M |
| Employees | 37 | 6 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed BMEA by 41.6 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Healthcare · Biotechnology · 37 employees
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Healthcare · Biotechnology · 6 employees
BMEA vs KZIA FAQ
Which is bigger, Biomea Fusion or Kazia Therapeutics?
Kazia Therapeutics (KZIA) is larger, with a market capitalization of $100.79M compared with $99.05M for Biomea Fusion (BMEA).
Which stock has performed better over the past year, BMEA or KZIA?
KZIA returned +23.18% over the past 12 months, compared with -18.45% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Kazia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.